APRIL levels are associated with disease activity in human chronic graft-versus-host disease

Chasset, François; Masson, Adèle de; Buanec, Hélène Le; Xhaard, Aliénor; Fontbrune, Flore Sicre de; Robin, Marie; Rybojad, M.; Parquet, Nathalie; Brignier, Anne; Coman, Téreza; Bengoufa, Djaouïda; Bergeron, Anne; Latour, Régis Peffault de; Bagot, Martine; Bensussan, Armand; Socié, Gérard; Bouaziz, Jean‐David

doi:10.3324/haematol.2016.145409

Cited by 9 publications

(11 citation statements)

References 15 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These differences are unlikely to have biased our findings on the association between BAFF levels and NRM as neither one of these factors was associated with NRM (Supplementary Table S5) or with BAFF levels (Supplementary Table S6) in this patient population. Consistent with our data, a history of acute GvHD 10 and time to cGvHD onset 12 did not affect BAFF levels in independent patient cohorts. Importantly, NRM (HR = 0.96, P = 0.9), OS (HR = 1.2, P = 0.6) and PFS (HR = 1.3, P = 0.4) rates did not differ between patients who were or were not evaluable for BAFF assessment.…”

Section: Resultssupporting

confidence: 91%

“…A significant association between elevated soluble BAFF levels and the diagnosis of cGvHD has consistently been shown in several patient cohorts, 9,10,12,27,28 and prior studies have shown an association between BAFF levels and cGvHD treatment response. 27,29 Consistent with findings in prior studies, 10 BAFF levels in our current study were more likely to be elevated before the diagnosis of cGvHD in patients who presented with intermediate or high BAFF levels; and we have now linked persistently elevated BAFF levels to NRM in newly diagnosed cGvHD patients.…”

Section: Discussionmentioning

confidence: 70%

“…Our definition of BAFF levels was statistically derived; however, the ranges of BAFF concentrations in the low, intermediate and high BAFF groups respectively corresponded to BAFF concentrations reported in non-transplanted healthy individuals (median 1 ng/mL) 10,12,24–26 , in patients with inactive cGvHD (median 5.7 ng/mL) 12 and in patients with active cGvHD (median 9.9 ng/mL) 12 . Of note, intermediate BAFF levels at the time of cGvHD diagnosis (median: 3.6 ng/mL, range 2.4–5.7 ng/mL) identified a group of patients at low risk for NRM.…”

Section: Discussionmentioning

confidence: 99%

“…Of these, soluble B-cell activating factor (BAFF), chemokine (C-X-C motif) ligand 9 (CXCL9) and elafin have been associated with the diagnosis of cGvHD 7–12 but their potential association with outcome remains unknown. In this study, we evaluate the association of these three soluble factors with non-relapse mortality (NRM) in a cohort of newly diagnosed cGvHD patients.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

B-cell activating factor (BAFF) plasma level at the time of chronic GvHD diagnosis is a potential predictor of non-relapse mortality

Saliba

Sarantopoulos

Kitko

et al. 2017

Bone Marrow Transplant

View full text Add to dashboard Cite

Biological markers for risk stratification of chronic GvHD (cGvHD) could improve the care of patients undergoing allogeneic hematopoietic stem cell transplantation. Increased plasma levels of B-cell activating factor (BAFF), chemokine (C-X-C motif) ligand 9 (CXCL9) and elafin have been associated with the diagnosis, but not with outcome in patients with cGvHD. We evaluated the association between levels of these soluble proteins, measured by ELISA at the time of cGvHD diagnosis and before the initiation of therapy, with non-relapse-mortality (NRM). Based on the log-transformed values, factor levels were divided into tertiles defined respectively as low, intermediate, and high levels. On univariable analysis, BAFF levels were significantly associated with NRM, whereas CXCL9 and elafin levels were not. Both low (≤2.3 ng/mL, hazard ratio (HR)= 5.8, P= 0.03) and high (>.7 ng/mL, HR=5.4, P =0.03) BAFF levels were associated with a significantly higher NRM compared with intermediate BAFF level. The significant effect of high or low BAFF levels persisted in multivariable analysis. A subset of cGvHD patients had persistently low BAFF levels. In conclusion, our data show that BAFF levels at the time of cGvHD diagnosis are associated with NRM, and also are potentially useful for risk stratification. These results warrant confirmation in larger studies.

show abstract

Section: Resultssupporting

confidence: 91%

Section: Discussionmentioning

confidence: 70%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

B-cell activating factor (BAFF) plasma level at the time of chronic GvHD diagnosis is a potential predictor of non-relapse mortality

Saliba

Sarantopoulos

Kitko

et al. 2017

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…B-cell activating factor (BAFF) was reported as critical regulator of normal B-cell homoeostasis [10]. Different authors found higher BAFF levels in patients with cGvHD [11][12][13][14].…”

Section: Discussionmentioning

confidence: 99%